Abstract
The first-line treatment in advanced pancreatic cancer (ACP) is well established by phase III studies, with protocols FOLFIRINOX (FF) and gemcitabine/ nab-paclitaxel (GN). There are no phase III specifying optimal sequencing after disease progression to these first lines. The use of nabpaclitaxel was approved in Brazil for ACP treatment in 2017 and there is no approval for lipossomal irinotecan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
